Expression of Major Histocompatibility Complex class II and costimulatory molecules in oral carcinomas in vitro;Expresión de las moléculas del Complejo Mayor de Histocompatibilidad clase II y moléculas co-estimuladoras en carcinomas orales in vitro

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 10, Issue 3, 2005, Pages 188-195

  Villarroel Dorrego, Mariana ^a,d   Speight, Paul M ^b   Barrett, A William ^c  

^a Universidad Santa Maria   (Venezuela)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c QUEEN VICTORIA HOSPITAL   (United Kingdom)

^d Instituto de Investigaciones Raul Vincentelli   (Venezuela)

Author keywords

CD40; CD80; CD86; Costimulatory molecules; Major Histocompatibility Complex; Oral epithelium; Oral squamous cell carcinoma

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; KERATINOCYTE; MOUTH CARCINOMA; T LYMPHOCYTE ACTIVATION;

ANTIGENIC MODULATION; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE; CELL LINE, TUMOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON-GAMMA, RECOMBINANT; KERATINOCYTES; LYMPHOCYTE ACTIVATION; MOUTH MUCOSA; MOUTH NEOPLASMS;

EID: 18744385503     PISSN: 16984447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev 2003;192:161-80.
2. Yokochi T, Holly RD, Clark EA. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol 1982;128:823-7.
3. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-9.
4. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Jr., Lombard LA et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-11.
5. Henry J, Miller MM, Pontarotti P. Structure and evolution of the extended B7 family. Immunol Today 1999;20:285-8.
6. Symington FW, Brady W, Linsley PS. Expression and function of B7 on human epidermal Langerhans cells. J Immunol 1993;150:1286-95.
7. Valle A, Aubry JP, Durand I, Banchereau J. IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Int Immunol 1991;3:229-35.
8. Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217-23.
9. Schweitzer AN, Borriello F, Wong RC, Abbas AK, Sharpe AH. Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J Immunol 1997;158:2713-22.
10. Najafian N, Khoury SJ. T cell costimulatory pathways: blockade for autoimmunity. Expert Opin Biol Ther 2003;3:227-36.
11. Vogel LA, Noelle RJ. CD40 and its crucial role as a member of the TNFR family. Semin Immunol 1998;10:435-42.
12. Gaspari AA, Sempowski GD, Chess P, Gish J, Phipps RP. Human epidermal keratinocytes are induced to secrete interleukin-6 and co-stimulate T lymphocyte proliferation by a CD40-dependent mechanism. Eur J Immunol 1996;26:1371-7.
13. Li J, Yang Y, Inoue H, Mori M, Akiyoshi T. The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin-10. Cancer Immunol Immunother 1996; 43:213-9.
14. Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997;25:1108-14.
15. Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 1999;125:82-8.
16. Lang S, Atarashi Y, Nishioka Y, Stanson J, Meidenbauer N, Whiteside TL. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Cell Immunol 2000;201:132-43.
17. Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG et al. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol 2001;19:791-8.
18. Farmer I, Freysdottir J, Dalghous AM, Fortune F. Expression of adhesion and activation molecules in human buccal epithelial cell lines and normal human buccal epithelium in situ. J Oral Pathol Med 2001;30:113-20.
19. Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E et al. CD40 activation as potential tool in malignant neoplasms. Tumori 2002;88: 361-6.
20. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM, Jr. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 1999;5:2261-70.
21. Loro LL, Ohlsson M, Vintermyr OK, Liavaag PG, Jonsson R, Johannessen AC. Maintained CD40 and loss of polarised CD40 ligand expression in oral squamous cell carcinoma. Anticancer Res 2001;21:113-7.
22. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996;184:1-8.
23. Byrne SN, Halliday GM. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress. Cancer Immunol Immunother 2003; 52:396-402
24. Rice SQ, Crane IJ, Scully C, Prime SS. Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. Scand J Immunol 1992;36:443-52.
25. Thomas DW, Matthews JB, Patel V, Game SM, Prime SS. Inflammatory cell infiltrate associated with primary and transplanted tumours in an inbred model of oral carcinogenesis. J Oral Pathol Med 1995;24:23-31.
26. Eck SC, Turka LA. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells. Cancer Immunol Immunother 1999;48:336-41.
27. Kedjarune U, Pongprerachok S, Arpornmaeklong P, Ungkusonmongkhon K. Culturing primary human gingival epithelial cells: comparison of two isolation techniques. J Craniomaxillofac Surg 2001;29:224-31.
28. Prime SS, Nixon SV, Crane IJ, Stone A, Matthews JB, Maitland NJ et al. The behaviour of human oral squamous cell carcinoma in cell culture. J Pathol 1990;160:259-69.
29. Friedman RM, Vogel SN. Interferons with special emphasis on the immune system. Adv Immunol 1983;34:97-140.
30. Li J, Farthing PM, Thornhill MH. Cytokine regulation of major histocompatibility complex antigen expression by human oral and skin keratinocytes. Arch Oral Biol 1996;41:533-8.
31. Crane IJ, Rice SQ, Luker J, de Gay L, Scully C, Prime SS. The expression of MHC antigens on cultured oral keratinocytes and relationship to malignancy. Br J Exp Pathol 1988;69:749-58.
32. Mutlu S, Matthews JB, Midda M, Scully C, Prime SS. MHC antigen expression in human oral squamous carcinoma cell lines. J Pathol 1991;165:129-36.
33. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984;83:88-90.
34. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon differentially regulates class II antigen expression and biosynthesis on cultured normal human keratinocytes. J Interferon Res 1985;5:23-32.
35. Volc-Platzer B, Leibl H, Luger T, Zahn G, Stingl G. Human epidermal cells synthesize HLA-DR alloantigens in vitro upon stimulation with gamma-interferon. J Invest Dermatol 1985;85:16-9.
36. Savage NW, Walsh LJ, Seymour GJ. Expression of class I and class II major histocompatibility complex antigens on oral mucosal epithelium. J Oral Pathol 1987;16:153-7.
37. Schwartz R, Momburg F, Moldenhauer G, Dorken B, Schirrmacher V. Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-Gamma. Int J Cancer 1985;35:245-50.
38. Matthews JB, Pitigala-Arachchi A, Crane IJ, Scully C, Prime SS. The relationship between epithelial Ia expression and the inflammatory cell infiltrate during experimental oral carcinogenesis. Virchows Arch A Pathol Anat Histopathol 1988;413:521-8.
39. Peguet-Navarro J, Dalbiez-Gauthier C, Moulon C, Berthier O, Reano A, Gaucherand M et al. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. J Immunol 1997;158:144-52.
40. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today 1998;19:502-6.
41. Mutis T, de Bueger M, Bakker A, Ottenhoff TH. HLA class II+ human keratinocytes present Mycobacterium leprae antigens to CD4+ Th1-like cells. Scand J Immunol 1993;37:43-51.
42. de Bueger M, Bakker A, Goulmy E. Human keratinocytes activate primed major and minor histocompatibility antigen specific Th cells in vitro. Transpl Immunol 1993;1:52-9.
43. Pawelec G, Kalbacher H, Pohla H, Boshell M, Max H, Friccius H et al. Requirements for stimulation or anergy induction in alloreactive human T cell clones. Cell Immunol 1994;158:241-52.
44. Thomas GR, Chen Z, Enamorado I, Bancroft C, Van Waes C. IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-gamma. Int J Cancer 2000;86:368-74.
45. Yang G, Hellstrom KE, Mizuno MT, Chen L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 1995;155(8):3897-903.
46. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S. Major histocompatibility complex class II+B7-1+tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:619-29.
47. Wang YC, Zhu L, McHugh R, Graham SD, Jr., Hillyer CD, Dillehay D et al. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation. J Immunother Emphasis Tumor Immunol 1996;19:1-8.
48. Grousson J, Concha M, Schmitt D, Peguet-Navarro J. Effects of CD40 ligation on human keratinocyte accessory function. Arch Dermatol Res 1998; 290:325-30.